Nanolive label-free live cell
A revolution for cell biology
imaging & analysis
Capture dynamic, unbiased live cell data to accelerate discovery, development and therapeutics
Nanolive delivers breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine screening, imaging and analysis to radically advance how scientists study living cells and provide novel biological insights such as the mechanisms of cancer and neurodegenerative diseases.
Nanolive imaging platforms allow scientists to explore living cells in 3D without damaging them. By delivering complete measurements and understandings on a sub-cellular scale (e.g. mitochondrial networks, stem cell differentiation), Nanolive technology allows screening across thousands of live cell populations, and potential therapeutic use of those same, unperturbed, cells.
Application fields such as drug discovery, immuno-oncology, mitochondria & cell metabolism, neuroscience
Groundbreaking technology (platforms & consumables)
Swiss high precision and quality
Over 200 units installed worldwide
Patented product & technology
12’000 ft² headquarters in Switzerland with an international Team in USA & Europe
More than 1’000 citations in scientific papers
A deep understanding of live cells and their dynamics
Our platforms, software, consumables and services are built on technology that is 100% non-invasive, thus circumventing the use of current end-point assays that damage cells.
This allows live cells to be imaged for an unlimited amount of time while characterizing their dynamics with the most reliable and quantitative results.
Our solutions are accelerating the drug discovery and development workflows of leading biopharma companies, transforming immuno-oncology, pathway discovery, mitochondrial & cell metabolism analysis, and sensitive cell line analytics. We are applying our technology to new research areas such as cell therapy manufacturing, regenerative medicine QA/QC and biotechnology.
Video: Antibodies being used as a T-cell targeting system to wipe out cancer cells
Invention of Nanolive technology
Incorporation of Nanolive SA at EPFL Innovation Park, a spin-off from EPFL
3D Cell Explorer
3D Cell Explorer-fluo
Yann Cotte, Ph.D.
Chief Executive Officer
Dr. Cotte holds a Master in Physics from the State University of New York and a PhD in Holographic Microscopy from the École Polytechnique Fédérale de Lausanne (EPFL) in Lausanne. Dr. Cotte made a fundamental discovery in microscopy during his PhD and co-founded Nanolive in 2013 where he holds since foundation the position of CEO.
Sébastien Equis, Ph.D.
Chief Technical Officer
Dr. Sébastien Equis holds a Master in Optics / Physics / Electronics from Institut d’Optique in Paris and a PhD from the École Polytechnique Fédérale de Lausanne (EPFL) in Lausanne. He co-founded Nanolive in 2013 where he holds the position of CTO and is the head of product development.
Lisa Pollaro, Ph.D.
Chief Marketing Officer
Dr. Lisa Pollaro holds a Master in Pharmaceutical Biotechnology from Padua University and a PhD in Biochemical Engineering from the École Polytechnique Fédérale de Lausanne (EPFL) in Lausanne. Dr. Pollaro manages the marketing and communication team of Nanolive.
Alexander Jones, Ph.D.
Chief Commercial Officer
Dr. Alexander Jones is a global life science leader and manages the commercial team of Nanolive. His experience covers commercial leadership roles; driving growth in large, matrix, life-science organisations, and building out small and mid-sized organisations across EMEAI, US and APAC. He holds a PhD in Phylogenetics & Molecular Biology.